DRDR:LSE:LSE-iShares Healthcare Innovation UCITS ETF USD (Acc) (GBX)

ETF | Others |

Last Closing

USD 615.625

Change

-6.88 (-1.10)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+0.38 (+0.14%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.41 (+0.28%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.39%)

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.05 (+0.30%)

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.30 (-0.48%)

USD 266.08B
0QZO:LSE 0QZO

+8.80 (+8.82%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.08 (+0.26%)

USD 218.91B
0QZ3:LSE Qualcomm Inc.

+2.23 (+1.38%)

USD 202.26B

ETFs Containing DRDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.03% 42% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.03% 43% F 48% F
Trailing 12 Months  
Capital Gain 16.90% 64% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.90% 64% D 62% D
Trailing 5 Years  
Capital Gain 28.40% 54% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.40% 54% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 2.95% 38% F 47% F
Dividend Return 2.95% 37% F 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.86% 32% F 48% F
Risk Adjusted Return 14.13% 33% F 46% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.